Clinical trial
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII…
NCT00157105 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00157105 |
|---|---|
| Title | Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery |
| Official title | Recombinant Antihemophilic Factor (rAHF PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Safety and Efficacy in Hemophilia A Patients Undergoing Surgical or Invasive Procedures |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Antihemophilic factor, recombinant, manufactured protein-free |
| Enrollment | 59 |
| Start date | Feb 12, 2001 |
| Primary completion | Aug 3, 2004 |
| Completion | Aug 3, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 24, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: